MDxHealth (MDXH) Q2 2026 Earnings Call Transcript
MDxHealth reported Q2 2026 revenue of $27.2M, up 16% YoY, with gross profit at $17.9M. Operating loss increased to $5.1M, and net loss rose 36% to $9.5M. The company completed the wind-down of its Resolve UTI business. Management expressed confidence in meeting full-year revenue guidance of $110M-$115M and returning to adjusted EBITDA profitability by year-end, citing growth in its urology and prostate cancer diagnostics.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh guidance and capital raise details, shaping short‑term price expectations.
Market read
First‑time disclosure of Q2 2026 financials and a $20M capital raise for MDxHealth, a small‑cap diagnostic company.
What to watch
The $20M direct placement may improve liquidity, but dilution and integration risk from the ExoDx acquisition remain.
Background
MDxHealth completed the wind‑down of its Resolve UTI business and classified it as discontinued, focusing on prostate‑cancer diagnostics.
Ticker impact
MDxHealth reported Q2 2026 results with $27.2M revenue, a 16% YoY increase and a $20M direct placement raise.
Short‑term downside pressure from higher operating loss, medium‑term upside if guidance is met.
The disclosed financials are the first public release of Q2 2026 data, providing fresh material for valuation models.
Market effects
Highlights growth in urology diagnostics and potential demand for AI‑enhanced pathology tests.
U.S. biotech and diagnostic sector may see modest re‑rating based on MDxHealth's guidance.
Limited; primarily affects niche precision‑diagnostics market.
Counterpoint
The operating loss and cash burn could signal deeper execution challenges despite revenue growth.
Key entities
- ExecutiveRon Kalfus
Chief Financial Officer presenting Q2 results.
- ExecutiveMichael McGarrity
CEO discussing strategic focus and clinical data.
